<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04513418</url>
  </required_header>
  <id_info>
    <org_study_id>RTS-011</org_study_id>
    <nct_id>NCT04513418</nct_id>
  </id_info>
  <brief_title>Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy</brief_title>
  <acronym>POINT</acronym>
  <official_title>Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hecheng Li M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningbo Medical Center Lihuili Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ruijin Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial will evaluate the effects of preoperative enteral&#xD;
      immunonutrition in esophageal cancer patients undergoing neoadjuvant therapy. The purpose of&#xD;
      this study is to determine whether preoperative immune-modulating diet before surgery can&#xD;
      improve the rate of complications and other perioperative outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Esophageal cancer ranks the fourth in mortality and the sixth in incidence among cancers in&#xD;
      China according to the latest report of cancer epidemiology. Although the development of&#xD;
      neoadjuvant therapy and radical esophagectomy have improved the prognosis of esophageal&#xD;
      cancer patients, dysphagia and digestive tract reconstruction can cause malnutrition and&#xD;
      infection-related complications. Postoperative enteral and parenteral nutrition have proved&#xD;
      to be effective in improving outcomes after esophagectomy. However, whether to provide a&#xD;
      preoperative nutritional support for patients with resectable esophageal cancer remains&#xD;
      controversial.&#xD;
&#xD;
      This prospective randomized controlled trial will evaluate the effects of preoperative&#xD;
      enteral immunonutrition in esophageal cancer patients undergoing neoadjuvant therapy. The&#xD;
      purpose of this study is to determine whether preoperative immune-modulating diet before&#xD;
      surgery can improve the rate of complications and other perioperative outcomes.&#xD;
&#xD;
      The sample size is estimated with the hypothesis that preoperative immunonutrition during the&#xD;
      neoadjuvant therapy can reduce postoperative nutrition and immune-related complications after&#xD;
      esophagectomy. According to the previously published articles, the required sample size of&#xD;
      interventional and control arm (ratio=2:1) was calculated as 137 cases and 69 cases to detect&#xD;
      the reduction in related complications from 50% to 30% based on a bilateral significance&#xD;
      level (α) of 0.05 and a power of test (1-β) of 0.80. Considering an estimated drop rate of&#xD;
      15%, the minimum sample size of this study is 244 patients, 162 cases in the interventional&#xD;
      group and 82 in the control group. After signing the informed consent, every eligible&#xD;
      participant will be randomized into either group based on a computer-generated random number.&#xD;
      Blinding will not be applied to patients and surgeons due to the difficulty in clinical&#xD;
      practice but outcomes assessor will be masked.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of postoperative nutrition and immune-related complications</measure>
    <time_frame>Up to 30 days after surgery</time_frame>
    <description>Rate of gastrointestinal complications (anastomotic leakage, gastrointestinal dysfunction), metabolic complications (electrolyte disturbances, liver or renal dysfunction) and infectious complications(wound infection, catheter-related infection, pneumonia, sepsis, or other infections requiring antibiotics).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Completion rate of neoadjuvant therapy and esophagectomy</measure>
    <time_frame>2-3 months before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events during neoadjuvant chemoradiotherapy</measure>
    <time_frame>2-3 months before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response rate (pCR)</measure>
    <time_frame>2-3 months before surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>At operation day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgery</measure>
    <time_frame>At operation day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgery-related complications</measure>
    <time_frame>At operation day</time_frame>
    <description>Conversion to open surgery, recurrent nerve injury, cardiac and cerebrovascular accident</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Postoperative in-hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization costs</measure>
    <time_frame>Postoperative in-hospital stay</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day and 90-day mortality</measure>
    <time_frame>Up to 90 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight loss</measure>
    <time_frame>From neoadjuvant chemoradiotherapy to 6 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative change in PG-SGA score</measure>
    <time_frame>From neoadjuvant chemoradiotherapy to 6 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative change in blood pressure</measure>
    <time_frame>From neoadjuvant chemoradiotherapy to 6 months after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative change in biochemical indicators</measure>
    <time_frame>From neoadjuvant chemoradiotherapy to 6 months after surgery</time_frame>
    <description>WBC, albumin, CRP, TNF-α, IL-6, IgA, IgG, IgM, insulin, C-peptide, glucose, hemoglobin, vitamin A, vitamin D, serum ferritin, transferrin receptor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EORTC QLQ-C30 and OES-18 scale</measure>
    <time_frame>1-year, 3-year, and 5-year after surgery</time_frame>
    <description>Quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>1-year, 3-year, and 5-year after surgery</time_frame>
    <description>Overall survival (OS) and progression-free survival (PFS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Daily dietary intake</measure>
    <time_frame>Through study completion, an average of 6 months</time_frame>
    <description>24 hour meal review every week</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <arm_group>
    <arm_group_label>Interventional group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive omega-3 fatty-acid enriched enteral nutritional emulsion from the start of neoadjuvant chemoradiotherapy until surgery. Patients are meanwhile encouraged to intake 25-30kcal/kg through regular food.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are encouraged to intake 25-30kcal/kg through regular food without supplemental nutritional support before esophagectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Preoperative immunonutrition</intervention_name>
    <description>Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting from the start of neoadjuvant chemoradiotherapy until surgery. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.</description>
    <arm_group_label>Interventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed esophageal cancer&#xD;
&#xD;
          -  Staging as cT2-T3, N0-3, M0 with the need of neoadjuvant therapy before radical&#xD;
             esophagectomy&#xD;
&#xD;
          -  Tolerance for oral intake (at least fluid diet)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤2&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.5 kg/m2 before recruitment&#xD;
&#xD;
          -  Patients approve and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Expected survival time less than 6 months&#xD;
&#xD;
          -  Complete dysphagia&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Unable to obey the interventions because of any reasons&#xD;
&#xD;
          -  Serious co-morbidities (cardiac, pulmonary, liver, kidney, brain, hematologic,&#xD;
             endocrine and other diseases) in patients who cannot tolerate neoadjuvant therapy&#xD;
             and/or surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hecheng Li, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ruijin Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hecheng Li, PhD, MD</last_name>
    <phone>00862164370045</phone>
    <phone_ext>664566</phone_ext>
    <email>lihecheng2000@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuqin Cao, MD</last_name>
    <phone>008613918933069</phone>
    <email>caoyuqin314@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mingsong Wang</last_name>
      <phone>00862123271699</phone>
      <email>wangmingsong@xinhuamed.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dingpei Han, PhD, MD</last_name>
      <phone>00862164370045</phone>
      <phone_ext>666112</phone_ext>
      <email>dmhan1985@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Su Yang, MD</last_name>
      <phone>00862164370045</phone>
      <phone_ext>666112</phone_ext>
      <email>ys19851021@sina.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhigang Li</last_name>
      <phone>00862122200000</phone>
      <email>zhigang_li_sch@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lijie Tan</last_name>
      <phone>00862164041990</phone>
      <email>tan.lijie@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningbo Medical Center Lihuili Hospital</name>
      <address>
        <city>Ningbo</city>
        <state>Zhejiang</state>
        <zip>315048</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiyu Shen</last_name>
      <phone>0086057487018701</phone>
      <email>ningbomblhlswy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2020</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ruijin Hospital</investigator_affiliation>
    <investigator_full_name>Hecheng Li M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Esophageal Neoplasms</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Enteral Nutrition</keyword>
  <keyword>Nutrition Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

